Carreras Postdoc Program Empowering Future Leaders to Fight Blood Cancers

Carreras Postdoc Program Empowering Future Leaders to Fight Blood Cancers

CarrerasLeaders is a new innovative and international postdoctoral programme, designed by Josep Carreras Leukaemia Research Institute (IJC), an independent, non-profit biomedical research institute that is part of the Government of Catalonia network of Research Centres (CERCA). IJC is the first European institute exclusively devoted to leukaemia and other malignant blood diseases. The aim of the programme is to fund 16 excellent postdoctoral researchers for a period of 36 months. The selection of the fellows is merit-based, founded on peer review in an open and transparent selection procedure. Carrerasleaders is addressed to boost career perspective of researchers from a three-dimensional perspective: leadership, independence, and consolidation. This is a world-wide unique postdoctoral program that covers the entire spectrum of research and innovation in blood cancers and goes from understanding disease biology to the implementation of products and processes in the market and into the clinical practice through the development of a global translational approach. Applicants will have complete freedom of research choice within the scope of blood cancers and will be offer highly attractive working conditions and a healthy, inspiring and creative working environment. CarrerasLeaders is designed based on the following objectives: 1. Training the next generation of scientist leaders to advance on the cure of blood cancers, multiplying each one’s skills sets and networks via targeted Career Development Plans and mentoring. 2. Improve the quality of blood cancers postdoctoral research training, more targeted addressed to the researchers and societal needs. 3. Enhanced cooperation and transfer knowledge between sectors and disciplines. 4. Enable outstanding junior researchers to develop their research careers to an advanced and more independent level in a leading institution such as IJC. 5. Increase the competitiveness of the IJC blood cancers community